COL6A3 and renal cell carcinoma: Aberrant CTHRC1 expression has been reported across several solid tumors and is correlated with poor prognosis, suggesting its potential as a therapeutic target in RCC.[72, 73, 74, 75]COL6A3 encodes the α3 subunit of type VI collagen, a key structural ECM protein involved in maintaining tissue integrity and regulating developmental processes.